PRETOMANID, approved by FDA in August 2019, is an antibiotic used for the treatment of patients with extensively drug-resistant, treatment-intolerant or nonresponsive multidrug-resistant pulmonary tuberculosis only in combination with bedaquiline and linezolid. Pretomanid contains imidazo[2,1-b][1,3]oxazine core.

We have made a set of Building Blocks, which contain such part – the perfect start for your research!